Roth MKM initiated coverage of Accuray with a Buy rating and $9 price target. The company has about 10% market share in the radiation oncology space and is now reliably generating cash, the analyst tells investors in a research note. The firm says expansion into the value priced segment with Tomo C in China and Helix in India in fiscal 2024 positions Accuray to compete more effectively in faster growing emerging market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARAY:
